But some people never achieved enough immunity to be protected against COVID-19.
It’s true that most Remicade patients experienced an improvement in the immune system’s response after the second vaccine dose, however, that wasn’t the case for all of them.
As the researchers have found out, a small percentage of Remicade patients did not achieve enough immunity to stay protected against COVID-19, even after the second vaccine shot. The authors of the study believe the “antibody testing and adapted vaccine schedules should be considered to protect these at-risk patients.”
Here’s Everything You Need to Know About Johnson & Johnson’s Vaccine. CLICK HERE to read more about this topic!